Can Fite Biopharma Ltd (ADR) (CANF) is Resumed by ROTH Capital to Buy

Can Fite Biopharma Ltd (ADR) (CANF) was Resumed by ROTH Capital to “Buy”. ROTH Capital advised their investors in a research report released on Oct 19, 2016.

Many Wall Street Analysts have commented on Can Fite Biopharma Ltd (ADR). Rodman & Renshaw Resumed Can Fite Biopharma Ltd (ADR) on Aug 29, 2016 to “Buy”, Price Target of the shares are set at $6.

Can Fite Biopharma Ltd (ADR) closed down -0.07 points or -2.79% at $2.44 with 39,414 shares getting traded on Friday. Post opening the session at $2.52, the shares hit an intraday low of $2.3601 and an intraday high of $2.53 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment RA treatment for the treatment of Keratoconjunctictivitis Sicca for the treatment of Glaucoma among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries Ultratrend Ltd EyeFite Ltd and OphathaliX Inc.

Can Fite Biopharma Ltd (ADR)

Leave a Reply

Can Fite Biopharma Ltd (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Can Fite Biopharma Ltd (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.